Article
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.
Blood cancer journal - 10 Jan 2018
Saygin Caner, Hirsch Cassandra, Przychodzen Bartlomiej, Sekeres Mikkael A, Hamilton Betty K, Kalaycio Matt, Carraway Hetty E, Gerds Aaron T, Mukherjee Sudipto, Nazha Aziz, Sobecks Ronald, Goebel Christopher, Abounader Donna, Maciejewski Jaroslaw P, Advani Anjali S
Abstract excerpt
Intermediate-risk acute myeloid leukemia (IR-AML) is a clinically heterogeneous disease, for which optimal post-remission therapy is debated. The utility of next-generation sequencing information in decision making for IR-AML has yet to be elucidated. We retrospectively studied 100 IR-AML patients, defined by European Leukemia Net classification, who had mutational information at diagnosis, received intensive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.